[The rapid activation of human LAK cells and their inhibition on ovarian cancer at the advanced stage].
The study of generation of LAK cells from cord blood following a brief exposure to interleukin-2 (IL-2) demonstrated that a short time induction (15min-1h) of lymphocytes by a high concentration of IL-2 resulted in the maturation of LAK proceusor cells and such activated cells expressed cytolytic activity comparable to that of routinely induced (cultured continuously in IL-2 for 3-7 days) lymphocytes. Serologic test showed that this efficiency was not inhibited by autoserum. The results of experimental therapy with the two kinds of LAK cells in nude mouse model of human ovarian cancer confirmed that both types of LAK cells had remarkable inhibitory effect on tumor growth. The preliminary trial in the treatment of advanced ovarian cancer with rapid-pulsed LAK cells suggested that this method may serve as a new approach in the clinical application of tumor immunotherapy.
Song
Y F
YF
Dong Fang Hospital, Fuzhou.
Zhao
Y N
YN
Li
J
J
D000818:Animals; D018283:Cystadenocarcinoma, Papillary / Q000473:pathology / Q000628:therapy*; D005260:Female; D006801:Humans; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000494:pharmacology; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D010051:Ovarian Neoplasms / Q000473:pathology / Q000628:therapy*; D014407:Tumor Cells, Cultured
D007376:Interleukin-2